Skip Navigation

European Heart Journal 2001 22(7):523-525; doi:10.1053/euhj.2000.2448
Copyright © 2001 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Kastrati, A.
Right arrow Articles by Schömig, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kastrati, A.
Right arrow Articles by Schömig, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Hotline Editorials

Good medicines for bad genes

A. Kastrati and A. Schömig

Deutsches Herzzentrum and 1. Med. Klinik rechts der Isar, Technische Universität München, Munich, Germany

References

  1. Goodall AH, Curzen N, Panesar M. Increased binding of fibrinogen to glycoprotein IIIa-Proline33 (HPA-1b, PlA2, Zwb) positive platelets in patients with cardiovascular disease. Eur Heart J. 1998;20:742–747
  2. Feng D, Lindpaintner K, Larson MG. Increased platelet aggregability associated with platelet GPIIIa PlA2 polymorphism: the Framingham Offspring Study. Arterioscler Thromb Vasc Biol. 1999;19:1142–1147[Abstract/Free Full Text]
  3. Lasne D, Krenn M, Pingault V. Interdonor variability of platelet response to thrombin receptor activation: influence of PlA2 polymorphism. Br J Haematol. 1997;99:801–807[CrossRef][ISI][Medline]
  4. Vijayan KV, Goldschmidt-Clermont PJ, Roos C, Bray PF. The Pl(A2) polymorphism of integrin beta(3) enhances outside-in signaling and adhesive functions. J Clin Invest. 2000;105:793–802[ISI][Medline]
  5. Michelson AD, Furman MI, Goldschmidt-Clermont P. Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists. Circulation. 2000;101:1013–1018[Abstract/Free Full Text]
  6. Byzova TV, Plow EF. The Pl(A2) allele and cardiovascular disease: the pro(33) and con [comment]. J Clin Invest. 2000;105:697–698[ISI][Medline]
  7. Walter DH, Schächinger V, Elsner M, Dimmeler S, Zeiher AM. Platelet glycoprotein IIIa polymorphisms and risk of coronary stent thrombosis. Lancet. 1997;350:1217–1219[CrossRef][ISI][Medline]
  8. Kastrati A, Koch W, Gawaz M. PlA polymorphism of glycoprotein IIIa and risk of adverse events after coronary stent placement. J Am Coll Cardiol. 2000;36:84–89[Abstract/Free Full Text]
  9. Kastrati A, Schömig A, Seyfarth M. PlApolymorphism of platelet glycoprotein IIIa and risk of restenosis after coronary stent placement. Circulation. 1999;99:1005–1010[Abstract/Free Full Text]
  10. Ross SD, Allen IE, Connelly JE. Clinical outcomes in statin treatment trials: a meta-analysis. Arch Intern Med. 1999;159:1793–1802[Abstract/Free Full Text]
  11. Serruys PW, Foley DP, Jackson G. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial. Eur Heart J. 1999;20:58–69[Abstract/Free Full Text]
  12. Walter DH, Schachinger V, Elsner M, Mach S, Auch-Schwelk W, Zeiher AM. Effect of statin therapy on restenosis after coronary stent implantation. Am J Cardiol. 2000;85:962–968[CrossRef][ISI][Medline]
  13. Kuivenhoven JA, Jukema JW, Zwinderman AH. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N Engl J Med. 1998;338:86–93[Abstract/Free Full Text]
  14. de Maat MP, Jukema JW, Ye S. Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis. Am J Cardiol. 1999;83:852–856[CrossRef][ISI][Medline]
  15. Walter DH, Schächinger V, Elsner M. Statin therapy is associated with reduced restenosis rates after coronary stent implantation in carriers of the PlA2allele of the platelet glycoprotein IIIa gene. Eur Heart J. 2001;22:587–595[Abstract/Free Full Text]
  16. Kastrati A, Dirschinger J, Schomig A. Genetic risk factors and restenosis after percutaneous coronary interventions. Herz. 2000;25:34–46[ISI][Medline]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Kastrati, A.
Right arrow Articles by Schömig, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kastrati, A.
Right arrow Articles by Schömig, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?